Ranger Randomised Controlled Trials
Explore the evidence-backed solution to overcome peripheral arterial disease (PAD) through the innovative use of Ranger the next-generation drug-coated balloon.
Boston Scientific is the first company to voluntarily evaluate our drug-coated balloon against another drug-coated balloon (DCB) in a level-1 randomised controlled trial for comparative effectiveness.
Ranger DCB has consistently demonstrated impressive results, with almost 90% patency at 12 months in both the RANGER II SFA and COMPARE trials.
RANGER II SFA is a prospective, multi-Center, randomised controlled trial Ranger™ Drug-Coated Balloon vs. Uncoated Balloon (3:1). Follow-up through 5-Years
COMPARE is the world’s first head-to-head prospective, RCT (1:1) comparing low dose Ranger™ DCB (2 μg/mm2) to higher dose IN.PACT™ DCB (3.5 μg/mm2)
Discover more